1125P Real-world molecular testing and treatment patterns in epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic Chinese non-small cell lung cancer patients failing first-line EGFR-tyrosine kinase inhibitors

P Tian,L Wu,C Zhou,J Tan,K Wang,F Luo,Y Liu,Y Guo,Y Li Y Li,Z Liu,Y Gong,Y Wang,W Li W Li

doi:10.1016/j.annonc.2022.07.1249

1125P Real-world molecular testing and treatment patterns in epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic Chinese non-small cell lung cancer patients failing first-line EGFR-tyrosine kinase inhibitors

P Tian, L Wu + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1249

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: West China Medical Center of Sichuan University, Hunan Cancer Hospital, First Affiliated Hospital of Guangzhou Medical University, Suzhou Municipal Hospital, West China Hospital of Sichuan University, First Affiliated Hospital of Sun Yat-sen University, Beijing Chest Hospital, Sichuan University

#Non-small Cell Lung Cancer Patients #Epidermal Growth Factor Receptor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Epidermal Growth Factor Receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients failing first-line (1L) EGFR- tyrosine kinase inhibitors (TKI) can benefit from subsequent targeted therapies. However, the real world data on the testing patterns and subsequent treatment patterns among patients failing 1L EGFR-TKI are lacking.

Full Text